- Home
- TLSA vs LRE Comparison
TLSA vs LRE Comparison
Compare TLSA & LRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TLSA | LRE |
|---|---|---|
| Founded | 2013 | 2001 |
| Country | United Kingdom | Japan |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.2M | 17.2M |
| IPO Year | 2017 | 2022 |
Fundamental Metrics
Financial Performance| Metric | TLSA | LRE |
|---|---|---|
| Price | $1.22 | $1.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 108.5K | 23.9K |
| Earning Date | 05-06-2025 | 07-30-2015 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.16 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $1.00 |
| 52 Week High | $2.60 | $2.86 |
Technical Indicators
Market Signals| Indicator | TLSA | LRE |
|---|---|---|
| Relative Strength Index (RSI) | 38.51 | 48.24 |
| Support Level | N/A | $1.34 |
| Resistance Level | $1.56 | $1.43 |
| Average True Range (ATR) | 0.09 | 0.09 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 8.62 | 16.84 |
Price Performance
Historical ComparisonAbout TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa Prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment units to individual customers in Japan and Dallas, Texas. Its revenue is predominantly generated from developing and selling single-family homes and condominiums, hotel operations, and residential leasing. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.